Is pharmacokinetic behavior of argirein , derived from rhein , characterized as slow release and prolonged T₁/₂ of rhein in rats?
The pharmacokinetic behavior of oral argirein presents a slow release property against those following oral rhein in rats. The released rhein following oral argirein is suitable in suppressing chronic inflammatory reactions attributed to prolonged T(1/2) and delayed T(max) due to its slow release pharmacokinetic characteristics.
While FMF angle and NB are independent markers for DS, their combination resulted in a minimal but nonsignificant improvement in DS detection.